Immunotherapy is using the immune system of the patient to combat the cancer and works in two different ways. It works by either forcing the immune system to seek out and kill the mesothelioma cells, or synthetic proteins can be introduced to help the immune system fight the disease by better recognizing and attacking the cancer cells.
Four different kinds of immunotherapy are already being used for treating cancer: immune checkpoint inhibitors, cancer vaccines, monoclonal antibodies and non-specific immunotherapies. Pembrolizumab is currently showing promise as a treatment for mesothelioma in clinical trials.
SELLAS collaborates with NIH to develop gene-monitoring assay for cancer immunotherapies.
